Daiichi Sankyo Co Ltd – Lobbying Governance & Transparency

Sign up to access all our data and the evidence and analysis underlying our overall scores. Once you've created an account, we'll get in touch with further details:

Lobbying Governance

Overall Assessment	Analysis	Score
Moderate	Daiichi Sankyo discloses a partial framework for keeping its policy engagement in line with its climate goals. It states that the company has “a public commitment … to conduct our engagement activities in line with the goals of the Paris Agreement,” and outlines a concrete mechanism for indirect lobbying alignment by noting that “当社サステナビリティ推進部のメンバーがリーダーとして参画し…主導的な役割を果たしています” in the climate-change task-force of the Japan Pharmaceutical Manufacturers Association, which led the industry body to adopt a “2050年カーボンニュートラル” vision and a 46 % CO₂-reduction target for 2030. This indicates the company is actively working to align at least one key trade association with its own climate commitments. Governance of wider environmental strategy is overseen by the “EHS経営委員会,” chaired by the Chief EHS Officer and reporting to the board twice a year, but the disclosure does not clarify whether this committee specifically reviews or approves lobbying positions, nor does it name any individual or board committee formally charged with monitoring lobbying alignment. We found no public description of a systematic, recurring review of the company’s direct lobbying, criteria for assessing other associations, or a published climate-lobbying alignment report. Overall, the company shows some mechanisms and commitments that indicate moderate governance of indirect climate-related lobbying, but the disclosure of monitoring procedures, responsible oversight parties and coverage of direct lobbying remains limited. View Sources	C

Overall Assessment

Analysis

Score

Moderate

Daiichi Sankyo discloses a partial framework for keeping its policy engagement in line with its climate goals. It states that the company has “a public commitment … to conduct our engagement activities in line with the goals of the Paris Agreement,” and outlines a concrete mechanism for indirect lobbying alignment by noting that “当社サステナビリティ推進部のメンバーがリーダーとして参画し…主導的な役割を果たしています” in the climate-change task-force of the Japan Pharmaceutical Manufacturers Association, which led the industry body to adopt a “2050年カーボンニュートラル” vision and a 46 % CO₂-reduction target for 2030. This indicates the company is actively working to align at least one key trade association with its own climate commitments. Governance of wider environmental strategy is overseen by the “EHS経営委員会,” chaired by the Chief EHS Officer and reporting to the board twice a year, but the disclosure does not clarify whether this committee specifically reviews or approves lobbying positions, nor does it name any individual or board committee formally charged with monitoring lobbying alignment. We found no public description of a systematic, recurring review of the company’s direct lobbying, criteria for assessing other associations, or a published climate-lobbying alignment report. Overall, the company shows some mechanisms and commitments that indicate moderate governance of indirect climate-related lobbying, but the disclosure of monitoring procedures, responsible oversight parties and coverage of direct lobbying remains limited.

View Sources

Lobbying Transparency

Overall Assessment	Analysis	Score
Limited	Daiichi Sankyo provides only limited insight into its climate-policy lobbying. It reports having spoken at the Japanese Ministry of the Environment’s “Decarbonization Management Promotion Network” study session in December 2020, which identifies one concrete mechanism (serving as a speaker) and a specific target entity (the Ministry), but it does not describe any other channels of engagement. The company indicates that the session focused on promoting Science-Based Targets as a tool for meeting the Paris Agreement’s 2 °C goal, yet it does not reference any particular piece of legislation or regulation linked to that objective. Likewise, it expresses a broad intention to encourage wider recognition and adoption of SBTs across industry but does not articulate the exact policy changes, amendments, or numerical goals it seeks. Overall, the disclosure shows that the company is active in at least one governmental forum, but the lack of detail on the precise policies involved, additional engagement methods, and the specific outcomes it is advocating keeps its transparency at a basic level.	D